The Enterprise Value as of December 2024 (TTM) for Exelixis, Inc. (EXEL) is 9.50B

According to Exelixis, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.50B. This represents a change of 34.25% compared to the average of 7.07B of the last 4 quarters.

Exelixis, Inc. (EXEL) Historical Enterprise Value (quarterly & annually)

How has EXEL Enterprise Value performed in the past?

The mean historical Enterprise Value of Exelixis, Inc. over the last ten years is 4.84B. The current 9.50B Enterprise Value has changed 19.52% with respect to the historical average. Over the past ten years (40 quarters), EXEL's Enterprise Value was at its highest in in the December 2017 quarter at 8.83B. The Enterprise Value was at its lowest in in the December 2014 quarter at 562.83M.

Exelixis, Inc. (EXEL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Exelixis, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Exelixis, Inc. (EXEL) Average Enterprise Value

How has EXEL Enterprise Value performed in the past?

The current Enterprise Value of Exelixis, Inc. (EXEL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Exelixis, Inc. (EXEL) Enterprise Value vs. Peers

How is EXEL’s Enterprise Value compared to its peers?

Exelixis, Inc.’s Enterprise Value is greater than TG Therapeutics, Inc. (5.08B), greater than Viking Therapeutics, Inc. (4.67B), greater than Madrigal Pharmaceuticals, Inc. (6.67B), greater than BioXcel Therapeutics, Inc. (81.77M), less than BioMarin Pharmaceutical Inc. (12.56B), less than Seagen Inc. (42.84B), less than Alnylam Pharmaceuticals, Inc. (31.45B), greater than Halozyme Therapeutics, Inc. (7.35B), greater than X4 Pharmaceuticals, Inc. (79.21M), greater than PDS Biotechnology Corporation (37.39M), greater than PTC Therapeutics, Inc. (3.39B), greater than Reata Pharmaceuticals, Inc. (6.64B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Krystal Biotech, Inc. (4.25B), greater than Kodiak Sciences Inc. (362.34M), less than Sarepta Therapeutics, Inc. (12.73B), greater than Mirati Therapeutics, Inc. (3.91B),

Build a custom stock screener for Exelixis, Inc. (EXEL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exelixis, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Exelixis, Inc. (EXEL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Exelixis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.